ES2109332T3 - Ciclopropilamino-1,3,5-triazinas sustituidas. - Google Patents

Ciclopropilamino-1,3,5-triazinas sustituidas.

Info

Publication number
ES2109332T3
ES2109332T3 ES92870101T ES92870101T ES2109332T3 ES 2109332 T3 ES2109332 T3 ES 2109332T3 ES 92870101 T ES92870101 T ES 92870101T ES 92870101 T ES92870101 T ES 92870101T ES 2109332 T3 ES2109332 T3 ES 2109332T3
Authority
ES
Spain
Prior art keywords
tiomorfolino
tiazolidinilo
cyclopropylamine
oxyxy
acetidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92870101T
Other languages
English (en)
Inventor
Keulen Berend Jan Van
Solo Golstein
Eric Cossement
Jean Gobert
Ernst Wulfert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Application granted granted Critical
Publication of ES2109332T3 publication Critical patent/ES2109332T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Epoxy Resins (AREA)

Abstract

NUEVAS CICLOPROPILAMINO-1,3,5-TRIAZINAS Y SUS SALES, SUS PROCESOS DE PREPARACION Y COMPOSICIONES TERAPEUTICAS. ESTOS COMPUESTOS RESPONDEN A LA FORMULA (I) EN LA QUE R1 = ALQUILO, CICLOALQUILO, ALQUILCICLOALQUILO, R2 = BIS(2-HIDROXIETIL)AMINO, 3-HIDROXI-1-ACETIDINILO, 3-METOXI1-ACETILDINILO, 3-OXO-1-ACETIDINILO, MORFOLINO, 4HIDROXIPIPERIDINO, TIOMORFOLINO, TIOMORFOLINO S-OXIDO, TIOMORFOLINO S,S-DIOXIDO, 3-TIAZOLIDINILO, 3-TIAZOLIDINILO SOXIDO, 3-TIAZOLIDINILO S,SDIOXIDO U 8-OXA-3-AZABICICLO[3,2,1]OCT3-ILO. ESTOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE LOS TRASTORNOS ASOCIADOS A LA ENFERMEDAD DE ALZHEIMER, A LAS DEMENCIAS SENILES DE TIPO ALZHEIMER Y A CUALQUIER PATOLOGIA COGNOCITIVA EVOLUTIVA, EN EL TRATAMIENTO DE LA DEPRESION, DE LA ANSIEDAD, DE LOS TRASTORNOS DEL HUMOR, DE LOS FENOMENOS INFLAMATORIOS Y EL ASMA.
ES92870101T 1991-07-25 1992-07-09 Ciclopropilamino-1,3,5-triazinas sustituidas. Expired - Lifetime ES2109332T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919116039A GB9116039D0 (en) 1991-07-25 1991-07-25 Substituted cyclopropylamino-1,3,5-triazines

Publications (1)

Publication Number Publication Date
ES2109332T3 true ES2109332T3 (es) 1998-01-16

Family

ID=10698941

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92870101T Expired - Lifetime ES2109332T3 (es) 1991-07-25 1992-07-09 Ciclopropilamino-1,3,5-triazinas sustituidas.

Country Status (21)

Country Link
US (2) US5258513A (es)
EP (1) EP0527117B1 (es)
JP (1) JP3138540B2 (es)
KR (1) KR100221400B1 (es)
AT (1) ATE159719T1 (es)
AU (1) AU648424B2 (es)
CA (1) CA2072680A1 (es)
DE (1) DE69222903T2 (es)
DK (1) DK0527117T3 (es)
ES (1) ES2109332T3 (es)
FI (1) FI923314A7 (es)
GB (1) GB9116039D0 (es)
GR (1) GR3026017T3 (es)
HU (1) HU218207B (es)
IE (1) IE922422A1 (es)
NO (1) NO300683B1 (es)
NZ (1) NZ243681A (es)
PL (2) PL169646B1 (es)
RU (1) RU2095353C1 (es)
UA (1) UA27749C2 (es)
ZA (1) ZA924920B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US6400819B1 (en) * 1996-03-28 2002-06-04 Hitachi, Ltd. Method and apparatus for executing communication in real-time and data structure for real-time data communication
WO1998011076A1 (de) * 1996-09-13 1998-03-19 Lonza Ag Verfahren zur herstellung von 6-methyl-2-methylamino-4-methoxy-1,3,5-triazin
US6292261B1 (en) 1998-05-22 2001-09-18 Cyberoptics Corporation Rotary sensor system with at least two detectors
US6538750B1 (en) 1998-05-22 2003-03-25 Cyberoptics Corporation Rotary sensor system with a single detector
FI105684B (fi) * 1998-08-21 2000-09-29 Neste Chemicals Oy Enantioselektiiviset kiraaliset sulfidikatalyytit, menetelmä niiden valmistamiseksi ja niiden käyttö stereoselektiivisiin epoksidointi-, syklopropanointi- ja atsiridinointireaktioihin
US6384032B1 (en) * 1999-06-17 2002-05-07 Shionogi Bioresearch Corp. Inhibitors of IL-12 production
EP1185528A4 (en) * 1999-06-17 2003-03-26 Shionogi Biores Corp INHIBITORS OF IL-12 PRODUCTION
CZ302882B6 (cs) 1999-08-21 2012-01-04 Nycomed Gmbh Farmaceutický prostredek
CN1098876C (zh) * 1999-09-21 2003-01-15 上海赛璐化工股份有限公司 一种长碳链共聚酰胺及其制备方法
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
US6680315B2 (en) * 2000-06-15 2004-01-20 Synta Pharmaceuticals Corp. Triazine compounds
MXPA04005181A (es) * 2001-11-30 2005-06-17 Synta Pharmaceuticals Corp Compuestos de pirimidina.
RU2234500C1 (ru) * 2002-11-15 2004-08-20 Кубанский государственный аграрный университет Способ получения простых макроэфиров сим-триазинового ряда
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
TWI359017B (en) * 2003-11-10 2012-03-01 Synta Pharmaceuticals Corp Heteroaryl-hydrazone compounds
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201391254A1 (ru) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. Способ получения агонистов гуанилатциклазы c
ES2657551T3 (es) * 2011-08-08 2018-03-05 Immunomet Therapeutics Inc. Derivados de biguanida sustituidos en N1-amina cíclica-N5, métodos de preparación de los mismos y composición farmacéutica que comprende los mismos
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
EP3492106B1 (en) 2013-08-09 2021-02-17 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160831A (en) * 1976-08-19 1979-07-10 Ciba-Geigy Corporation Novel insecticides
EP0003749B1 (de) * 1978-02-03 1982-09-15 Ciba-Geigy Ag 2-Methylthio-4-cyclopropylamino-6-(Alpha,Beta-dimethylpropylamino)-s-triazin und die Verwendung von Triazinderivaten als Meerwasseralgizide
GB8819494D0 (en) * 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
GB8819493D0 (en) * 1988-08-16 1988-09-21 Ucb Sa 2-amino-4-morpholino-6-propyl-1 3 5-triazines

Also Published As

Publication number Publication date
HU218207B (hu) 2000-06-28
EP0527117B1 (fr) 1997-10-29
EP0527117A1 (fr) 1993-02-10
KR930002327A (ko) 1993-02-23
NO300683B1 (no) 1997-07-07
HU9202441D0 (en) 1992-10-28
FI923314A0 (fi) 1992-07-21
JP3138540B2 (ja) 2001-02-26
NO922922D0 (no) 1992-07-23
KR100221400B1 (ko) 1999-09-15
GB9116039D0 (en) 1991-09-11
NO922922L (no) 1993-01-26
GR3026017T3 (en) 1998-04-30
AU2053492A (en) 1993-01-28
UA27749C2 (uk) 2000-10-16
ATE159719T1 (de) 1997-11-15
DE69222903T2 (de) 1998-03-26
NZ243681A (en) 1997-06-24
ZA924920B (en) 1993-04-28
IE922422A1 (en) 1993-01-27
US5258513A (en) 1993-11-02
JPH06220026A (ja) 1994-08-09
AU648424B2 (en) 1994-04-21
RU2095353C1 (ru) 1997-11-10
US5348956A (en) 1994-09-20
PL169646B1 (pl) 1996-08-30
DK0527117T3 (da) 1998-05-18
PL169247B1 (pl) 1996-06-28
HUT66218A (en) 1994-10-28
FI923314L (fi) 1993-01-26
FI923314A7 (fi) 1993-01-26
PL295403A1 (es) 1993-02-08
DE69222903D1 (de) 1997-12-04
CA2072680A1 (en) 1993-01-26

Similar Documents

Publication Publication Date Title
ES2109332T3 (es) Ciclopropilamino-1,3,5-triazinas sustituidas.
ES2037208T3 (es) Un metodo para preparar derivados 3-aminometilicos de indano, indolina, dihidrobenzofurano y dihidrobenzotiofeno.
MX9307810A (es) Heterociclicos no aromaticos sustituidos con aminometileno.
ES2113574T3 (es) Derivados del acido pentanoico.
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2089672T3 (es) N-fenilacetaminonitrilos y su empleo como productos intermedios para la sintesis de 3-aril-pirrolidin-2,4-dionas insecticidas y acaricidas.
AR009052A1 (es) Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas
ATE94384T1 (de) Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
PE110498A1 (es) Tioesteres y cetonas heterociclicos
HU9600278D0 (en) Remedy for nervous diseases
ES2123039T3 (es) Nuevas 3-(hidroxi-bencilidenil)-indolin-2-onas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
GT199600100A (es) Procedimientos para hacer compuestos heterociclicos.
ES2160596T3 (es) Derivados de quinuclidina como antagonistas de la sustancia p.
AR038045A1 (es) Agentes terapeuticos
ES2166379T3 (es) 2-aminotetralinas sustituidas.
DE69502130D1 (de) Polyenderivate, diese enthaltende pharmazeutische und kosmetische Zusammensetzungen und ihre Verwendung
ES2149777T3 (es) Derivados de triazol que tienen actividad antifungica.
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2123873T3 (es) Pirrolocarbazol.
ES2141787T3 (es) Derivados de la 1,2,3,4-tetrahidro-9-acridinamina.
ES2062455T3 (es) Nuevos derivados de benzonaftiridina-1,8, su preparacion y las composiciones que les contienen.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2070002T3 (es) Composiciones terapeuticas a base de derivados de 1,2-ditiol-3-tiona.
ES2061530T3 (es) 9-amino-1,4-etano-1,2,3,4-tetrahidroacridina y compuestos afines, intermediarios y un procedimiento para la preparacion de los mismos y su uso como medicamentos.
BG97201A (bg) Цис-2,3,3а,4,5,9в-хексахидро-1н-бензо(е)- индолови производни

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 527117

Country of ref document: ES